Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Robert Schueren, William McKenzie

Premium

WaferGen has made changes to its board of directors following the firm's acquisition of IntegenX's next-gen sequencing library prep business. The company has reduced the size of its board of directors to seven from nine. In addition, Robert Schueren, IntegenX's CEO, will join WaferGen's board of directors. Prior to his role at IntegenX, Schueren was vice president and general manager of genomics at Agilent Technologies.

The board also appointed William McKenzie as a director, effective Dec. 30, 2013. Most recently, he served as president and general manager of molecular diagnostics at PerkinElmer.

Scott Davidson and Joseph Pesce, representatives of Great Point Partners, stepped down from the board, effective Dec. 30, 2013.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.